152 related articles for article (PubMed ID: 25450584)
1. The role of signaling pathways in cervical cancer and molecular therapeutic targets.
Manzo-Merino J; Contreras-Paredes A; Vázquez-Ulloa E; Rocha-Zavaleta L; Fuentes-Gonzalez AM; Lizano M
Arch Med Res; 2014 Oct; 45(7):525-39. PubMed ID: 25450584
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling.
Li H; Jiao S; Li X; Banu H; Hamal S; Wang X
Biochem Biophys Res Commun; 2015 Nov; 467(1):14-20. PubMed ID: 26427870
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of RAS/β-catenin interactions.
Zeller E; Hammer K; Kirschnick M; Braeuning A
Arch Toxicol; 2013 Apr; 87(4):611-32. PubMed ID: 23483189
[TBL] [Abstract][Full Text] [Related]
4. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
5. Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer.
Kavitha K; Kowshik J; Kishore TK; Baba AB; Nagini S
Biochim Biophys Acta; 2013 Oct; 1830(10):4433-44. PubMed ID: 23726989
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
7. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
9. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
Ramachandran I; Thavathiru E; Ramalingam S; Natarajan G; Mills WK; Benbrook DM; Zuna R; Lightfoot S; Reis A; Anant S; Queimado L
Oncogene; 2012 May; 31(22):2725-37. PubMed ID: 22002305
[TBL] [Abstract][Full Text] [Related]
10. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
Vilchez V; Turcios L; Marti F; Gedaly R
World J Gastroenterol; 2016 Jan; 22(2):823-32. PubMed ID: 26811628
[TBL] [Abstract][Full Text] [Related]
12. A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways.
Kim D; Rath O; Kolch W; Cho KH
Oncogene; 2007 Jul; 26(31):4571-9. PubMed ID: 17237813
[TBL] [Abstract][Full Text] [Related]
13. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
14. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase.
Srinivas KP; Viji R; Dan VM; Sajitha IS; Prakash R; Rahul PV; Santhoshkumar TR; Lakshmi S; Pillai MR
Oncotarget; 2016 Apr; 7(17):24154-71. PubMed ID: 26992219
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
16. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
Kang DW; Lee BH; Suh YA; Choi YS; Jang SJ; Kim YM; Choi KY; Min DS
Clin Cancer Res; 2017 Dec; 23(23):7340-7350. PubMed ID: 28939743
[No Abstract] [Full Text] [Related]
17. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
Chen C; Chang YC; Lan MS; Breslin M
Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
[TBL] [Abstract][Full Text] [Related]
18. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.
Chung MT; Lai HC; Sytwu HK; Yan MD; Shih YL; Chang CC; Yu MH; Liu HS; Chu DW; Lin YW
Gynecol Oncol; 2009 Mar; 112(3):646-53. PubMed ID: 19095296
[TBL] [Abstract][Full Text] [Related]
19. Sulfiredoxin May Promote Cervical Cancer Metastasis via Wnt/β-Catenin Signaling Pathway.
Lan K; Zhao Y; Fan Y; Ma B; Yang S; Liu Q; Linghu H; Wang H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28448437
[TBL] [Abstract][Full Text] [Related]
20. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
